Nicola Arrighi

Should we be cautious on the use of commercially available antibodies to dopamine receptors?

Serena Bodei, Nicola Arrighi, PierFranco Spano et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 2008 · 57 citations

Functional Selectivity, Medicine, Available Antibodies +7

Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma

Alessandro Antonelli, Regina Tardanico, Piera Balzarini et al. · Cancer Genetics and Cytogenetics · 2010 · 47 citations

Type 1, Urology, Cytogenetic Features +9

Surgical treatment of atypical metastasis from renal cell carcinoma (RCC)

Alessandro Antonelli, Nicola Arrighi, Serena Corti et al. · British Journal of Urology · 2012 · 40 citations · Full text

Pre-existing type-2 diabetes is not an adverse prognostic factor in patients with renal cell carcinoma: A single-center retrospective study

Alessandro Antonelli, Nicola Arrighi, Serena Corti et al. · Urologic Oncology Seminars and Original Investigations · 2012 · 25 citations

Urology, Medicine, Pre-existing Type-2 Diabetes +8

Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases

Nicola Arrighi, Serena Bodei, Danilo Zani et al. · Pharmacological Research · 2013 · 24 citations · Full text

Muscle Function, Signal Transduction, Molecular Physiology +11